FDA Approves First Treatment for Breast Cancer With a Certain Inherited Genetic Mutation

This is a major breakthrough for women with this inherited genetic mutation. It is the first time a drug has been developed to treat women with metastatic breast cancer who have a “BRCA” gene mutation. Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research said “This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of a cancer, often across cancer types.”

Read more from the journal Metastatic Breast Cancer here.